Digital Therapeutics for Digestive Disease Patients
- Business, Digital Therapeutics, Tech

Digital Therapeutics for Digestive Disease Patients

Nori Health starts ADJUVANT, a clinical study, to investigate the impact of its digital therapy app on digestive disease patients.

Utrecht, The Netherlands, May 10, 2022 – Nori Health, a digital health startup focused on inflammatory diseases, announced today that the first patients had started the pilot phase of ADJUVANT, a clinical trial of the digital therapy program in the Nori Health app. The study is being conducted in The Netherlands in collaboration with THINC (The Healthcare Innovation Center, UMC Utrecht) at the Elisabeth-TweeSteden Hospital (ETZ) in Tilburg and the Radboudumc hospital in Nijmegen.

The research focuses specifically on people living with chronic intestinal disorders, Crohn’s disease, or ulcerative colitis. Previous studies1, 2 show that the quality of life for bowel patients is lower when compared to healthy individuals and that many patients can take a more active role in self-management of their condition to improve this. Self-management can provide health benefits for patients and lead to lower healthcare costs.

For this, Nori Health has developed a digital therapy app to coach and support patients based on various proven methods such as cognitive-behavioral therapy (CBT). In terms of content, the Nori Health app is based on scientific insights that show a positive change in patients with Crohn’s disease or ulcerative colitis in lifestyle, well-being, and mental resilience.

In the Nori Health app, patients have access to a 6-week digital program in which they have interactive sessions with digital coach Nori, primarily through chat conversations. Challenges and experiences can be shared here, and patients receive personalized insights and tips to organize their daily lives better.

See also  Join Industry Leaders at World Class Digital Health 2022

Jaap Trappenburg of research institute THINC, and principal investigator of the study, says: “In principle, apps are not always complex to make. The challenge lies in how the app offers a substantial solution to a patient’s needs while simultaneously providing health benefits or efficiency. By gaining insight into the working mechanism of the app as well as the experiences of the users, the app can be further optimized, increasing the chance that the app is used optimally, leading to actual health gains and possible cost reduction.”

Roeland Pater, founder, and CEO of Nori Health, adds: “We see a great future for value-driven care in which digital applications play an important role in addition to traditional treatment. With this study, we want to explore how Nori Health can help patients take more active ownership of their care to improve their quality of life.”

The ADJUVANT study starts with a pilot phase of 50 patients, after which a second decisive phase will be launched later this year with at least 150 patients, in which there is also room for an expansion of the number of hospitals involved.

For more information:

  1. Knowles SR, Graff LA, Wilding H, et al. Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses – Part 1. Inflamm Bowel Dis 2018;24(4):742-51.
  2. Greene J, Hibbard JH, Sacks R, et al. When patient activation levels change, health outcomes and costs change, too. Health Af 2015;34(3):4317.

About digital therapy / digital therapeutics (DTx)

See also  Why Hospital Design Matters More Than We Know

Digital therapeutics (DTx) deliver medical interventions directly to patients using evidence-based, clinically evaluated software to treat, manage and prevent a broad spectrum of diseases and conditions.

DTx products are held to the same evidence and regulatory oversight standards as traditional medical treatments. In addition, these digital therapies must adhere to all ten core principles to demonstrate product safety, efficacy, quality, patient-centricity, privacy, and continued clinical impact.

For more information about DTx:

About Nori Health

Nori Health was founded in 2019 by a team led by Roeland Pater, a Crohn’s patient himself and someone active in digital care for many years, alongside support from the EU Horizon 2020 program. The company focuses on developing digital therapeutics (DTx) for inflammatory diseases based on proven methodology, such as cognitive behavioral therapy, and based on hundreds of scientific studies on improvements in quality of life. Nori Health received a seed investment in 2021 from Healthy Capital from Amsterdam and angel investors. The company works closely with patient associations, pharmaceutical companies, and hospitals.

Digital Therapeutics for Digestive Disease Patients